Schizophrenia Clinical Trials in Phoenix

Showing 101-120 of 136 trials

CAFE Comparison of Atypicals in First Episode of Psychosis

NCT00034892

The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.

SchizophreniaPsychotic DisordersMental Health+1 more

AstraZenecaStarted Mar 2002

Stanford, California, United States • Miami, Florida, United States • Atlanta, Georgia, United States +23 more locations

TERMINATEDPhase 3290 miles

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

NCT00366704

The purpose of this study is to determine the effect of bifeprunox or risperidone on the body weight of patients with schizophrenia.

Schizophrenia

Wyeth is now a wholly owned subsidiary of Pfizer400 participantsStarted Nov 2006

Little Rock, Arkansas, United States • Little Rock, Arkansas, United States • Anaheim, California, United States +63 more locations

CAFE Comparison of Atypicals in First Episode of Psychosis

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

Schizophrenia Trials in Other Cities

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Study Evaluating Vabicaserin in Subjects With Schizophrenia

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

A Long-Term, Open-Label, Study on Schizophrenia

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia

Improving Antipsychotic Adherence Among Patients With Serious Mental Illness

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease

Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia

Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

Other Conditions in Phoenix